Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-04 21:29 | 2025-08-13 | DMAC | DiaMedica Therapeutics Inc. | STAHLBERG JAN | 10% owner | BUY | $5.96 | 1,000,000 | $5,958,100 | 7,764,465 |
| 2025-09-04 23:50 | 2025-09-02 | OCUL | OCULAR THERAPEUTIX, INC | Notman Donald | Officer | SELL | $12.43 | 1,066 | $13,250 | 308,807 |
| 2025-09-04 21:54 | 2025-08-26 | NATR | NATURES SUNSHINE PRODUCTS INC | Yates Bryant J | Officer | SELL | $16.74 | 9,672 | $161,919 | 97,498 |
| 2025-09-05 03:28 | 2025-09-03 | IONS | IONIS PHARMACEUTICALS INC | LOSCALZO JOSEPH | Director | OPT+S | $60.15 | 16,000 | $962,371 | 36,330 |
| 2025-09-05 00:47 | 2025-09-02 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | SELL | $162.26 | 467 | $75,775 | 45,522 |
| 2025-09-05 04:01 | 2025-09-02 | NKTR | NEKTAR THERAPEUTICS | ROBIN HOWARD W | Director, Officer | SELL | $30.16 | 1,500 | $45,240 | 67,840 |
| 2025-09-05 03:37 | 2025-09-03 | IONS | IONIS PHARMACEUTICALS INC | KLEIN JOSEPH III | Director | OPT+S | $60.00 | 28,000 | $1,680,000 | 0 |
| 2025-09-05 00:48 | 2025-09-02 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | SELL | $128.62 | 6,000 | $771,690 | 429,973 |
| 2025-09-05 00:26 | 2025-09-02 | INSM | INSMED Inc | Smith Michael Alexander | Officer | OPT+S | $143.89 | 24,272 | $3,492,379 | 54,902 |
| 2025-09-05 00:24 | 2025-09-02 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | OPT+S | $144.34 | 186,648 | $26,941,276 | 83,111 |
| 2025-09-05 02:59 | 2025-09-02 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $70.49 | 20,000 | $1,409,848 | 5,487 |
| 2025-09-05 02:56 | 2025-09-02 | CORT | CORCEPT THERAPEUTICS INC | Lyon Joseph Douglas | Officer | OPT+S | $70.25 | 5,000 | $351,248 | 10,066 |
| 2025-09-05 02:54 | 2025-09-02 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $70.49 | 20,000 | $1,409,828 | 7,681 |
| 2025-09-05 02:54 | 2025-09-02 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $70.53 | 40,000 | $2,821,032 | 2,821,370 |
| 2025-09-04 14:53 | 2025-09-02 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $417.64 | 22,500 | $9,396,837 | 0 |
| 2025-09-05 03:29 | 2025-09-02 | IONS | IONIS PHARMACEUTICALS INC | BENNETT C FRANK | Officer | OPT+S | $59.14 | 38,909 | $2,301,265 | 101,570 |
| 2025-09-05 03:38 | 2025-09-02 | IONS | IONIS PHARMACEUTICALS INC | PARSHALL B LYNNE | Director | SELL | $50.91 | 20,000 | $1,018,298 | 66,344 |
| 2025-09-05 03:34 | 2025-09-02 | IONS | IONIS PHARMACEUTICALS INC | WENDER JOSEPH H | Director | SELL | $57.58 | 28,000 | $1,612,156 | 108,835 |
| 2025-09-04 23:44 | 2025-09-03 | ANIP | Ani Pharmaceuticals Inc. | Pera Antonio R | Director | SELL | $94.94 | 7,292 | $692,302 | 22,660 |
| 2025-09-03 23:33 | 2025-09-02 | LQDA | Liquidia Corp | Moomaw Scott | Officer | OPT+S | $28.63 | 70,692 | $2,023,672 | 155,254 |
| 2025-09-03 23:33 | 2025-09-02 | LQDA | Liquidia Corp | Schundler Russell | Officer | OPT+S | $29.05 | 1,063 | $30,880 | 580,098 |
| 2025-09-03 23:32 | 2025-08-29 | LQDA | Liquidia Corp | Krepp Sarah | Officer | SELL | $29.05 | 209 | $6,071 | 143,130 |
| 2025-09-03 23:30 | 2025-08-29 | LQDA | Liquidia Corp | Boyle Dana | Officer | SELL | $29.05 | 296 | $8,599 | 186,649 |
| 2025-09-04 00:16 | 2025-08-29 | SION | Sionna Therapeutics, Inc. | Ridloff Elena | Officer | SELL | $25.09 | 9,584 | $240,441 | 38,532 |
| 2025-09-04 00:31 | 2025-09-03 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $35.50 | 15,091 | $535,731 | 44,452 |
| 2025-09-03 23:31 | 2025-09-02 | LQDA | Liquidia Corp | Kaseta Michael | Officer | OPT+S | $29.05 | 1,148 | $33,349 | 358,448 |
| 2025-09-03 13:04 | 2025-08-28 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | Director | SELL | $1.97 | 6,572 | $12,947 | 703,294 |
| 2025-09-03 13:02 | 2025-08-28 | SPRO | Spero Therapeutics, Inc. | Keutzer Timothy | Officer | SELL | $1.97 | 1,695 | $3,339 | 739,744 |
| 2025-09-04 01:53 | 2025-09-02 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer | SELL | $16.26 | 18,428 | $299,639 | 97,994 |
| 2025-09-04 00:53 | 2025-09-02 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $19.87 | 5,501 | $109,325 | 18,469 |
| 2025-09-04 00:50 | 2025-08-29 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | OPT+S | $20.11 | 22,117 | $444,808 | 11,831 |
| 2025-09-04 00:51 | 2025-08-29 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. MD | Director | SELL | $20.13 | 61,885 | $1,245,696 | 91,585 |
| 2025-09-03 20:06 | 2025-09-02 | APLS | Apellis Pharmaceuticals Inc. | Chopas James George | Officer | SELL | $28.08 | 548 | $15,386 | 53,657 |
| 2025-09-04 02:57 | 2025-08-29 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.78 | 4,870 | $8,675 | 1,904,755 |
| 2025-09-03 23:56 | 2025-09-03 | KNSA | Kiniksa Pharmaceuticals International, plc | Megna Michael R | Officer | OPT+S | $34.84 | 11,000 | $383,240 | 38,011 |
| 2025-09-04 01:46 | 2025-09-02 | BMY | BRISTOL MYERS SQUIBB CO | Elkins David V | Officer | SELL | $47.33 | 56,000 | $2,650,480 | 167,379 |
| 2025-09-03 23:20 | 2025-09-02 | AMPH | Amphastar Pharmaceuticals Inc. | Petersen Floyd F. | Director | SELL | $30.98 | 500 | $15,492 | 76,531 |
| 2025-09-03 23:56 | 2025-08-29 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Smith Thomas B | Officer | SELL | $38.42 | 17,478 | $671,576 | 70,264 |
| 2025-09-04 01:00 | 2025-09-02 | ACAD | Acadia Pharmaceuticals Inc. | GAROFALO ELIZABETH A. | Director | SELL | $25.98 | 1,600 | $41,560 | 25,382 |
| 2025-09-03 00:02 | 2025-08-28 | LQDA | Liquidia Corp | Saggar Rajeev | Officer | SELL | $27.85 | 20,000 | $557,072 | 249,727 |
| 2025-09-03 00:03 | 2025-08-28 | LQDA | Liquidia Corp | Adair Jason | Officer | OPT+S | $27.88 | 26,508 | $738,956 | 172,980 |
| 2025-09-03 04:50 | 2025-08-25 | STTK | Shattuck Labs, Inc. | Ashiya Mona | Director | BUY | $0.87 | 6,306,127 | $5,471,826 | 1,051,021 |
| 2025-09-03 03:30 | 2025-09-02 | RNA | Avidity Biosciences, Inc. | Gallagher Kathleen P. | Officer | SELL | $47.42 | 188 | $8,915 | 50,204 |
| 2025-09-02 20:05 | 2025-08-28 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $2.85 | 10,000 | $28,532 | 70,907 |
| 2025-09-03 02:46 | 2025-08-28 | LQDA | Liquidia Corp | Manning Paul B | Director | SELL | $28.26 | 670,837 | $18,957,451 | 430,828 |
| 2025-09-03 02:11 | 2025-09-02 | AXSM | Axsome Therapeutics, Inc. | JEFFS ROGER | Director | SELL | $123.68 | 13,464 | $1,665,228 | 57,510 |
| 2025-09-02 23:10 | 2025-08-29 | ALNY | Alnylam Pharmaceuticals Inc. | Tanguler Tolga | Officer | SELL | $448.37 | 3,474 | $1,557,650 | 25,992 |
| 2025-09-02 23:39 | 2025-09-02 | UTHR | UNITED THERAPEUTICS Corp | CAUSEY CHRISTOPHER | Director | OPT+S | $423.21 | 3,000 | $1,269,630 | 4,865 |
| 2025-09-03 00:00 | 2025-08-28 | PTCT | PTC THERAPEUTICS, INC. | Jacobson Allan Steven | Director | SELL | $50.15 | 1,667 | $83,600 | 17,451 |
| 2025-09-02 23:41 | 2025-09-02 | CYTK | CYTOKINETICS INC | Kaye Edward M. MD | Director | SELL | $50.00 | 6,756 | $337,800 | 23,230 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.